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ABSTRACT
Background Elaﬁn is a potent endogenous neutrophil
elastase inhibitor that protects against myocardial
inﬂammation and injury in preclinical models of
ischaemic-reperfusion injury. We investigated whether
elaﬁn could inhibit myocardial ischaemia-reperfusion
injury induced during coronary artery bypass graft
(CABG) surgery.
Methods and results In a randomised double-blind
placebo-controlled parallel group clinical trial, 87
patients undergoing CABG surgery were randomised
1:1 to intravenous elaﬁn 200 mg or saline placebo
administered after induction of anaesthesia and prior to
sternotomy. Myocardial injury was measured as cardiac
troponin I release over 48 h (area under the curve
(AUC)) and myocardial infarction identiﬁed with MRI.
Postischaemic inﬂammation was measured by plasma
markers including AUC high-sensitive C reactive protein
(hs-CRP) and myeloperoxidase (MPO). Elaﬁn infusion
was safe and resulted in >3000-fold increase in plasma
elaﬁn concentrations and >50% inhibition of elastase
activity in the ﬁrst 24 h. This did not reduce myocardial
injury over 48 h (ratio of geometric means (elaﬁn/
placebo) of AUC troponin I 0.74 (95% CI 0.47 to 1.15,
p=0.18)) although post hoc analysis of the high-sensitive
assay revealed lower troponin I concentrations at 6 h
in elaﬁn-treated patients (median 2.4 vs 4.1 μg/L,
p=0.035). Elaﬁn had no effect on myocardial infarction
(elaﬁn, 7/34 vs placebo, 5/35 patients) or on markers
of inﬂammation: mean differences for AUC hs-CRP of
499 mg/L/48 h (95% CI −207 to 1205, p=0.16), and
AUC MPO of 238 ng/mL/48 h (95% CI −235 to 711,
p=0.320).
Conclusions There was no strong evidence that
neutrophil elastase inhibition with a single-dose elaﬁn
treatment reduced myocardial injury and inﬂammation
following CABG-induced ischaemia-reperfusion injury.
Trial registration number (EudraCT 2010-019527-
58, ISRCTN82061264).
INTRODUCTION
Ischaemia-reperfusion injury occurs when blood
ﬂow is restored to organs and tissues that have sus-
tained a period of interrupted blood supply. This
occurs following therapies for acute myocardial
infarction and ischaemic stroke, and is a necessary
consequence of solid organ transplantation.
Mechanisms of cell and tissue injury include a
neutrophil-mediated postischaemic inﬂammatory
response and activation of cellular death pathways
following reperfusion.1 Protecting organs from
ischaemia-reperfusion injury to improve clinical
outcome is a high priority. Despite intense research
efforts and huge promise from preclinical and
early-phase clinical trials, there are currently no
effective therapies that can limit this injurious
response.
During coronary artery bypass graft (CABG)
surgery and cardiopulmonary bypass, coronary
blood ﬂow is interrupted and the heart is put into
circulatory arrest. This causes ischaemia-reperfusion
injury that is exacerbated by adverse neutrophil-
mediated myocardial inﬂammation and injury.2–4
CABG surgery therefore represents a programmed
clinical model of ischaemia-reperfusion injury that
lends itself to testing the efﬁcacy of potential thera-
peutic interventions.5
Elaﬁn is an endogenous anti-inﬂammatory
protein that was ﬁrst isolated in the search for inhi-
bitors of neutrophil elastase activity in the lung and
skin.6 7 It has inhibitory activity against both
human neutrophil elastase and proteinase-3 as well
as suppressing production of inﬂammatory cyto-
kines such as interleukin (IL)-8 and tumour necrosis
factor alpha (TNF-α).8 Elaﬁn is produced locally at
sites of inﬂammation, raising a local defence of
‘alarm’ antiproteases in order to contain and inhibit
neutrophil-mediated inﬂammation.9 Cardiovascular
tissues do not express elaﬁn or other neutrophil
elastase inhibitors, and are therefore more vulner-
able to neutrophil-mediated injury.
Augmentation of human elaﬁn has consistently
demonstrated impressive protective effects in rodent
models of ischaemic and inﬂammatory elastase-
mediated vascular injury. Elaﬁn infusion reduced
muscular injury and neutrophil recruitment in the
rat ischaemic hindlimb and myocardial ischaemia–
reperfusion injury models.10 11 Transgenic mice
overexpressing human elaﬁn under the control of
the vascular pre-proendothelin promoter have rela-
tively preserved LV size and function following
myocardial infarction.12 Compared with wild-type
littermates, these animals are also protected from
viral myocarditis and hypoxia-induced pulmonary
hypertension and exhibit less restenosis following
wire-induced carotid artery denudation.13–15 Elaﬁn
augmentation, therefore, protects the cardiovascular
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system from a range of conditions characterised by neutrophil
elastase-mediated inﬂammation and injury.
The purpose of the Elaﬁn Myocardial Protection from
Ischemia Reperfusion (EMPIRE) randomised-controlled clinical
trial was to provide proof of concept that Elaﬁn treatment could
reduce myocardial ischaemia-reperfusion inﬂammation and
injury in patients undergoing CABG surgery.
METHODS
Trial population
Between June 2011 and September 2013, consecutive patients
referred for elective CABG surgery were recruited from two
clinics at Edinburgh Heart Centre. Patients were 18 years or
older, and were referred for isolated CABG surgery requiring
two or more grafts. Exclusion criteria included patients with
recent myocardial infarction (within 1 month of surgery), emer-
gency or concomitant valve surgery, signiﬁcant renal impairment
(estimated glomerular ﬁltration rate<40 mL/min), severe
respiratory disease (maintenance corticosteroid therapy or
forced expiratory volume in 1 s <50% predicted), severe LV
impairment (EF <40%), contraindication to magnetic resonance
scanning, treatment for chronic inﬂammatory disease, women of
childbearing potential and inability to provide consent.
Study drug and randomisation
Intravenous recombinant human elaﬁn (Proteo Biotech AG,
Germany) 200 mg or saline placebo was prepared and infused
as aqueous solution of 250 mL 0.9% saline. Patients were ran-
domised (1:1) to receive elaﬁn or matched placebo by
Edinburgh Clinical Trials Unit to ensure allocation concealment.
Randomisation incorporated minimisation for age, presence of
diabetes mellitus, extent of coronary artery disease, renal func-
tion and surgeon A or B. To ensure blinding, study drugs were
prepared by staff independent of the study investigators or clin-
ical team responsible for the patient’s care.
Intravenous elaﬁn 200 mg causes complete inhibition of
plasma elastase activity for 2 h and >50% inhibition for 6 h.
This dosage regimen was selected to cover the increased elastase
release following CABG surgery that peaks at the time of
weaning from cardiopulmonary bypass and has returned to
baseline by 6–7 h. The study drug was administered to the
patient through a central venous cannula over a period of 30
min. The intravenous infusion was started at ﬁrst skin incision
and completed at least 20 min before cardiopulmonary bypass
commenced.
Anaesthesia and coronary artery bypass surgery
General anaesthesia was maintained with isoﬂurane and propo-
fol infusion during bypass. Surgical approach was via a median
sternotomy and cardiopulmonary bypass was started after
heparin administration with a non-pulsatile ﬂow and a mem-
brane oxygenator. Cardioprotection was provided by cold blood
cardioplegia (1:4), which was administered antegradely, after
cross-clamping the aorta, into the coronary arteries or by cross-
clamp ﬁbrillation.
Blood samples
Blood samples were taken at baseline (time 0, skin incision) and
at 2, 6, 24 and 48 h postoperatively. Plasma cardiac troponin I
(cTnI) concentrations were measured with the ARCHITECTSTAT
troponin I assay and ARCHITECTSTAT high-sensitive troponin I
assay (Abbott Laboratories, Abbott Park, Illinois, USA) validated
in our institution.16 17 Plasma concentrations of high-sensitive C
reactive protein, IL-6, IL-8, myeloperoxidase and elastase were
quantiﬁed using ELISAs (R&D Systems, UK; Elastase ELISA,
Cambridge Biosciences, UK). Plasma elastase activity and serum
elaﬁn concentrations were measured by the Department of
Dermatology, University of Kiel, Germany.
Cardiac MRI and analysis
Each patient underwent cardiac MRI twice: within 6 weeks
before surgery and from 5 days after surgery. Patients were
scanned using a research-dedicated 3T Siemens Verio scanner
(Siemens Medical, Germany). Quantiﬁcation of LV mass, EF and
late gadolinium enhancement infarct size were determined using
established protocols and dedicated cardiac analysis software by
two trained independent blinded observers.
Statistical analysis
The primary outcome variable was the 48 h area under the
curve (AUC) for plasma cTnI concentration. It was analysed
using a generalised linear model, including terms for the treat-
ment allocation and the variables on which the randomisation
was minimised. Log transformations were applied as the data
were skewed, and the results have been unlogged and presented
as geometric means. Secondary outcome measures involving the
AUC (hs-CRP, IL-6, IL-8, myeloperoxidase and elastase) were
analysed similarly, taking log transformation if the data were
skewed. LVEF and mass were analysed using QMass software
(Medis Medical Imaging Systems, the Netherlands). The change
in volume of infarction from preoperative and ﬁrst postoperative
magnetic resonance scans was categorised as increased, no
change or reduced according to detection threshold based on
interobserver variability. Post hoc analyses of individual time
points used Wilcoxon tests.
The primary analysis included all randomised patients on an
intention-to-treat basis regardless of compliance with allocated
treatment and post-randomisation events. A secondary pre-
speciﬁed exploratory analysis of AUC cTnI release excluded
patients who had myocardial infarction or a cardiac arrest,
resulting in loss of cardiac output for >1 min. Type V myocar-
dial infarction was deﬁned according to the third universal def-
inition.18 Finally, post hoc, we examined treatment effect for
each time point using the high-sensitive cTnI assay.
Power calculations were based on a recent study of patients
undergoing remote ischaemic preconditioning before coronary
artery bypass surgery.5 Mean cardiac troponin T release quanti-
ﬁed as AUC was 36.12 mg/L (SD 26.08) and 20.58 mg/L (SD
9.58) in the control and treated patients, respectively. No con-
temporary AUC data were available for cTnI release in this
patient group, but the measurements are equivalent in terms of
quantifying myocardial injury. With a sample size of 80 patients,
we had 90% power to detect this 40% difference in AUC cTnI
with a signiﬁcance level of 5%, using a t test with unequal var-
iances and allowing for four dropouts in each arm.
RESULTS
A participant ﬂow diagram is shown in ﬁgure 1. In 85 of the 87
patients, the trial infusion was administered as planned. Patient
characteristics and intraoperative details are shown in table 1.
Full data to calculate the AUC for cTnI (primary outcome) were
obtained in 83 patients (95%). Data quality was similarly good
for all secondary end points with missing data evenly balanced
across the treatment arms.
Elaﬁn infusion resulted in >3000-fold higher plasma concen-
trations (mean AUC at 24 h; 31.1±9.6 vs 0.01±0.07 μg/mL for
placebo) that was associated with a marked reduction in plasma
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elastase activity (mean AUC at 24 h; 4.28±5.13 vs 9.66
±9.21 units/mL; ﬁgure 2).
There was no change in mean AUC troponin concentrations
over the ﬁrst 48 h in Elaﬁn-treated patients (adjusted ratio of
geometric means (elaﬁn/placebo) 0.74, 95% CI 0.47 to 1.15,
p=0.18; ﬁgure 3). There remained no evidence of a difference
in a pre-speciﬁed secondary analysis where three patients who
sustained a clinical myocardial infarction or had a cardiac arrest
were excluded from analysis. Post hoc analysis using the high-
sensitive assay demonstrated a reduction of plasma cTnI concen-
trations in elaﬁn-treated patients at 6 h (median 2.4 vs placebo
4.1 μg/L, p=0.035; table 2).
Data from preoperative and postoperative scans were available
for 34 (77.3%) elaﬁn-treated and 35 (81.4%) placebo-treated
patients (table 3). There was no difference in postoperative
LV mass. The intra-class correlation coefﬁcient for late
gadolinium enhancement was 0.99 and the coefﬁcient of repeat-
ability of 1.78 mL (1.87 g) giving a threshold of 1.8 mL (1.9 g)
for an increase in late gadolinium enhancement. Using this
threshold, the incidence of increased myocardial infarction
volume was 20.3% in elaﬁn-treated and 14.3% in placebo-
treated patients.
There was no effect on peak myeloperoxidase concentrations
(mean difference 54.73 ng/L, 95% CI −60.0 to 169.5, p=0.35)
but peak elastase concentration was reduced (mean difference
−168.4 ng/mL, 95% CI −323.4 to −13.47, p=0.03; ﬁgure 4).
In contrast, there was no effect on the 6 h AUC for plasma elas-
tase concentration (mean difference –524.0 ng/mL/48 h, 95%
CI −1239 to 191.3, p=0.15). Although hs-CRP, IL-6 and IL-8
concentrations rose following CABG surgery (p<0.001 for all),
there was no treatment effect of elaﬁn (mean differences for 48
h AUC hs-CRP of 499 mg/L/48 h, 95% CI −207 to 1205,
p=0.16) and p>0.05 for both IL-6 and IL-8; ﬁgure 4.
Median duration of stay in the intensive care unit was 24 and
23 h for patients treated with elaﬁn and placebo, respectively
(HR 1.25, 95% CI 0.81 to 1.94, p=0.32). Clinical outcomes
Figure 1 Trial ﬂow diagram.
Table 1 Baseline characteristics and intraoperative details by
treatment group
Baseline characteristics Placebo Elafin
Age 63.6±8.4 63.9±7.7
Two-vessel coronary disease 12(27.9) 11(25.0)
Three-vessel coronary disease 31(72.1) 33(75.0)
Creatinine (mg/dL) 0.92±0.18 0.94±0.23
Diabetes mellitus 9 (20.9) 11 (25.0)
Surgeon A 16 (37.2) 18 (40.9)
Surgeon B 27 (62.8) 26 (59.1)
Male gender 36 (83.7) 38 (86.4)
EuroSCORE 2.21±1.73 2.64±2.06
Intraoperative details
Number of bypass grafts
One 1 2
Two 19 14
Three 14 22
Four 9 5
Five 0 1
Cardiopulmonary bypass time (min) 77±26 78±26
Cross clamp time (min) 45±15 47±16
Data are number of patients (%) or mean±SD.
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and the incidence of perioperative complications in the ﬁrst
48 h were also similar (table 4).
DISCUSSION
This is the ﬁrst phase II clinical trial investigating the effect of
elaﬁn, an endogenous neutrophil elastase inhibitor, on myocar-
dial ischaemia-reperfusion injury in patients undergoing CABG
surgery. Despite achieving >3000-fold increase in plasma con-
centrations sufﬁcient to more than halve plasma elastase activity,
we did not demonstrate clear evidence of beneﬁcial effect of
human recombinant elaﬁn in our patients. Speciﬁcally, we were
unable to attenuate the systemic inﬂammatory response despite
evidence of anti-inﬂammatory activity in preclinical disease
models.19 Nor could we conclusively detect a reduction in two
very sensitive, complementary and gold standard measures of
myocardial injury: AUC for plasma cTnI concentrations and late
gadolinium enhancement on MRI despite preclinical studies
with elaﬁn reducing myocardial inﬂammation and injury after
myocardial infarction.11 12 Differences between preclinical
studies and the clinical CABG surgery model may have been
responsible for different results. Elaﬁn has never been tested in
large animal models or in the setting of cardiopulmonary bypass
surgery. The surgical population was relatively low risk, and the
use of isoﬂurane anaesthesia may provide cardioprotection.20
Nevertheless, ischaemia-reperfusion injury in CABG surgery
produced conditions where elaﬁn would be expected to exert a
treatment effect: neutrophil activation, elastase release and
heightened circulating elastase activity together with activation
of inﬂammatory cytokine pathways.
Elaﬁn was safe and well tolerated in this high-risk clinical
setting and post hoc analysis indicated reduced myocardial
injury at 6 h, raising the possibility that more extensive treat-
ment effect could have been seen with multiple doses or bolus
and sustained infusions.
All patients in our trial exhibited evidence of myocardial
injury demonstrated by cTnI release. This was associated with a
marginal reduction in LVEF detected on postoperative MRI.
Small increases in delayed gadolinium enhancement indicative
of new myocardial infarction were detected in a ﬁfth of patients
in keeping with subclinical myocardial injury and infarction that
follows circulatory arrest and ischaemia-reperfusion during
CABG surgery. The current MRI results contrast with an earlier
study reporting increased infarct volume in 78% of patients
undergoing planned CABG.21 A key difference that may explain
this discrepancy is the detailed patient characterisation in our
study with availability of preoperative MRI scans allowing iden-
tiﬁcation of small areas of pre-existing infarct that would be
missed by using clinical history, echocardiography or ECGs to
screen for pre-existing infarction.
Our data indicate that with single bolus administration elaﬁn
does not confer myocardial protection in the ﬁrst 48 h following
CABG surgery. This result was unchanged in a secondary analysis
excluding patients who had sustained clinical events thought to
be unrelated to study drug that would have contributed to large
additional cTnI elevations. The absence of a convincing beneﬁ-
cial effect conﬂicts with preclinical ischaemia-reperfusion studies
where elaﬁn infusion was associated with a 27% reduction in
myocardial infarct size and improved LV performance. Our clin-
ical CABG model allows recapitulation of a key condition in
Figure 2 Perioperative plasma elaﬁn
concentration (left) and plasma
elastase activity (right) between
groups. Data are median plus IQR from
the ﬁrst skin incision (time 0 h) to
24 h. Placebo group n=41; elaﬁn
group, n=43.
Figure 3 Myocardial injury. Cardiac troponin I release following
coronary artery bypass graft surgery between treatment groups from
ﬁrst skin incision (time 0 h) to 48 h. Data are median plus IQR. Placebo
group, n=42; elaﬁn group, n=44.
Table 2 Post hoc analysis of plasma cardiac troponin I
concentration (μg/L, median and IQR, high-sensitive assay) to 48 h
Time (h) Placebo (n=43) Elafin (n=44) p Wilcoxon
0 0.00 (0.0–0.0) 0.00 (0.0–0.0) 0.861
2 0.08 (0.0–0.2) 0.07 (0.0–0.1) 0.228
6 4.07 (2.0–6.4) 2.41 (1.0–4.6) 0.035
24 1.02 (0.6–3.9) 1.08 (0.5–2.3) 0.421
48 0.53 (0.2–1.9) 0.47 (0.2–1.2) 0.648
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preclinical models where elaﬁn is administered upfront or
expressed in tissues prior to the onset of cardiopulmonary
bypass and ischaemic tissue injury. However, despite this, we
were unable to demonstrate clear efﬁcacy using two complemen-
tary and highly sensitive measures of myocardial injury. Post hoc
analysis identiﬁed a reduction in plasma cTnI concentrations at
6 h in elaﬁn-treated patients. Preclinical studies used continuous
elaﬁn delivery by infusion or gene expression and the reduced
cTnI concentration at an early postoperative time point raises the
question whether continuous elaﬁn infusion following the bolus
may have extended the treatment effect to 48 h.
Elaﬁn is one of several agents targeting inﬂammatory path-
ways that have been investigated in ischaemia-reperfusion injury
during cardiac surgery without success. Pexelizumab, a recom-
binant, single-chain anti-C5 monoclonal antibody, was studied
in two multicentre, randomised clinical trials of patients under-
going CABG surgery with or without valve surgery on cardio-
pulmonary bypass. There was no difference in the primary
outcome of death or myocardial infarction between the pexeli-
zumab and placebo treatment groups.22 Failure of treatment
effect with elaﬁn and pexelizumab may reﬂect different mechan-
isms responsible for myocardial injury during CABG.
Myocardial ischaemia and necrosis undoubtedly occur during
CABG surgery, and the magnitude of cTnI release is correlated
with subsequent morbidity and mortality.23 Mechanism of
ischaemia in preclinical models commonly involves complete
interruption of coronary blood ﬂow with a ligature to the
beating heart. In CABG surgery, the heart is in a state of circula-
tory arrest with protective cardioplegia and the impact of blood
Table 3 MRI analysis of postoperative EF, LV mass and infarct
volume
Placebo (n=35) Elafin (n=34)
Change in EF (%) −0.62±6.2 −2.4±6.3
Change in LV mass (g) 1.2±3.8 2.0±3.8
Change in infarct volume (%)
Reduced volume 2.9 0
No change 82.9 79.4
Increased volume 14.3 20.6
Figure 4 Perioperative circulating concentrations of neutrophil granule proteins elastase (top left), myeloperoxidase (top right), inﬂammatory
cytokines interleukin (IL)-6 (bottom left) and IL-8 (bottom right) between treatment groups out to 6 h. Data are median plus IQR. Placebo group,
n=42; elaﬁn group, n=44.
Table 4 Postoperative complications and outcomes by treatment
Placebo Elafin
Postoperative complications and outcomes (48 h)
Death 0 (0) 0 (0)
Stroke 0 (0) 0 (0)
Myocardial infarction 0 (0) 1 (2.3)
Inotrope or balloon pump support for >24 h 10 (27.3) 12 (23.3)
Red cell transfusion postoperative 12 (27.9) 12 (27.3)
Reoperation for bleeding 2 (4.7) 1 (2.3)
Respiratory complications 3 (7.0) 5 (11.4)
Antibiotic administration 2 (4.7) 4 (9.1)
Atrial fibrillation 4 (9.3) 3 (6.8)
Serum creatinine (mg/dL)
24 h 0.90±0.32 0.87±0.32
48 h 0.96±0.48 0.88±0.42
Data are number of patients (%) or mean±SD.
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ﬂow interruption is less severe. Despite evidence of neutrophil-
mediated inﬂammatory injury post-CABG, it may be activation
of cellular survival pathways within cardiomyocytes that deter-
mines the outcome of ischaemia-reperfusion in this setting.
Ischaemic preconditioning refers to resistance to acute myocar-
dial ischaemia reperfusion conferred by the application of brief
repeated episodes of ischaemia. This approach has been used
successfully in CABG surgery to limit cardiac marker release.5
We demonstrated substantial (>50%) inhibition of circulating
elastase activity by elaﬁn following CABG surgery, and our data
therefore indicate that neutrophil-derived elastase injury is not a
prominent cause of myocardial injury in this setting.
The patients in our study did have evidence of neutrophil
activation and degranulation with increased plasma concentra-
tions of the primary granule contents, elastase and myeloperoxi-
dase. Peak elastase concentrations were reduced in elaﬁn-treated
patients, although there was no demonstrable effect on peak
myeloperoxidase concentrations. This discrepancy is explained
by differences in the origin of these two neutrophil primary
granule proteins. Circulating human neutrophil elastase is
derived largely from acute neutrophil degranulation. A pool of
neutrophil-derived myeloperoxidase is transcytosed and bound
to the subendothelial matrix.24 This contributes to the circulat-
ing pool and is released following heparin administration during
cardiopulmonary bypass.25
Elaﬁn-mediated reductions in elastolytic activity and myelo-
peroxidase staining (as a marker of neutrophil inﬁltration) have
been consistent ﬁndings in preclinical models. Elaﬁn infusion
produced impressive reductions in myocardial inﬂammation and
necrosis in rabbits undergoing heterotopic cardiac transplant-
ation.26 This was associated with a marked attenuation of myo-
cardial elastolytic activity in transplanted hearts. Transgenic
mice overexpressing full-length human elaﬁn under the control
of the vascular pre-proendothelin promoter exhibit complete
inhibition of tissue elastolytic activity following acute myocar-
dial infarction and carotid arterial wire denudation.12 15 These
favourable treatment effects consistently occurred with reduced
tissue myeloperoxidase content in keeping with less neutrophil
recruitment. We were not able to access myocardial tissue for
assessment of neutrophil inﬁltration and elastolytic activity, but
the signiﬁcant reduction in peak elastase concentration leaves
open the possibility of an elaﬁn effect on neutrophil activation
and degranulation, which, if present, was not large enough to
translate into a reduction in AUC elastase at 6 h.
The EMPIRE patients exhibited increased IL-8 and IL-6 pro-
duction and increased levels of circulating hs-CRP in keeping
with a postischaemic inﬂammatory response following CABG
surgery. A systemic inﬂammatory response follows CABG
surgery driven both by major surgical insult and contact activa-
tion of blood with artiﬁcial surfaces of the extracorporeal
circuit.27 Belief that the magnitude of this response may drive
clinical outcome has led to trials examining interventions to
reduce postoperative inﬂammation. Peak and AUC hs-CRP, IL-6
and IL-8 release were similar between treatment groups. This
result for elaﬁn contrasts with previous work indicating broad-
ranging anti-inﬂammatory activity in human endothelial cells
and monocyte-derived macrophages.8 The failure of elaﬁn to
suppress IL-8 production during CABG surgery may indicate
that additional inﬂammatory pathways are active or that despite
impacting on circulating elastase activity elaﬁn is not reaching or
is not active in the subcellular space between neutrophils and
their target tissue.
Given lack of a conclusive therapeutic effect on myocardial
injury and postischaemic inﬂammation, it is not surprising that
the exploratory clinical end point of postoperative ITU stay was
no different between treatment groups. Elaﬁn infusion was safe.
There were no drug-related adverse events in this high-risk sur-
gical group and no evidence of excessive bleeding, cardiovascu-
lar complications or renal dysfunction.
In conclusion, despite the body of work indicating thera-
peutic potential from several groups using different models,
species and modes of augmentation, elaﬁn’s promise as a thera-
peutic agent to attenuate myocardial ischaemia-reperfusion
injury and inﬂammation was not translated in this ﬁrst phase II
clinical trial. Post hoc analysis identiﬁed reduced cTnI concen-
trations at 6 h in elaﬁn-treated patients, and it is possible that a
bigger dose could have conferred protection out to 48 h. Elaﬁn
was safe and lack of treatment effect was seen despite achieving
high plasma elaﬁn concentrations and halving of circulating
elastase activity.
Key messages
What is already known on this subject?
Ischaemia-reperfusion contributes to myocardial injury during
cardiac surgery. Therapies to reduce injury remain elusive
despite promise from preclinical studies. Elaﬁn is an endogenous
neutrophil elastase inhibitor with broad-ranging
anti-inﬂammatory activity. Elaﬁn reduces myocardial injury and
infarct size and is associated with better myocardial function in
preclinical models of ischaemia-reperfusion injury.
What might this study add?
We investigated elaﬁn in myocardial ischaemia-reperfusion
injury induced during coronary artery bypass graft surgery.
A single dose of elaﬁn was safe and reduced circulating elastase
activity but did not attenuate ischaemia-reperfusion injury or
postoperative inﬂammation following coronary artery bypass
surgery.
How might this impact on clinical practice?
Elaﬁn’s promise as a therapeutic agent was not translated in
this ﬁrst phase II clinical trial. Post hoc analysis revealed
reduced myocardial injury at an early time point in elaﬁn-treated
patients. Further studies with continuous infusion and
alternative clinical models are needed to elucidate whether
elaﬁn can confer protection form ischaemia-reperfusion injury.
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